Compare Travere Therapeutics Inc. Common Stock (TVTX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs GeneDx Holdings Corp — how do they compare? Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B), while GeneDx Holdings Corp trades at $67.94 (market cap $2.04B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 2.5× GeneDx Holdings Corp's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| TVTX | WGS | |
|---|---|---|
Market Cap | $5.02B | $2.04B |
Volume | 2,060,842 | 962,082 |
Sector | Health | Health |
52-Week High | $67.52 | $167.51 |
52-Week Low | $26.79 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $5.15B | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
GeneDx Holdings (WGS) trades at $64.96, up 1.79% today, showing mixed technical signals with a bearish moving average trend but bullish oscillators. Fundamentally, the company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows a net loss of -$106M. Recent news highlights product launches and CEO recognition, while analyst sentiment remains strongly positive with 91% buy ratings.
The outlook for WGS is cautiously optimistic with strong analyst support and operational improvements, but significant risks persist including negative profitability margins and high valuation multiples. The consensus price target of $81 suggests 25% upside potential, though investors should monitor cash flow trends and competitive pressures in the genomics diagnostics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
